Combination therapies for the treatment of Alzheimer's disease and related disorders
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
1. A method of treating a disease or condition in a subject in need thereof comprising co-administering about 10 mg/day of ibuprofen, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury; the second compound is selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365; and the ibuprofen and the second compound, taken together, are therapeutically effective.
2. The method of claim 1 , wherein the ibuprofen is formulated as a pill, capsule, or liquid.
3. The method of claim 1 , wherein the ibuprofen is co-administered orally.
4. A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering about 10 mg/day of ibuprofen, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury; the second compound is selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365, and the ibuprofen and the second compound, taken together, are therapeutically effective.
5. The method of claim 4 , wherein the ibuprofen is formulated as a pill, capsule, or liquid.
6. The method of claim 4 , wherein the ibuprofen is co-administered orally.